Collegium Pharma (NASDAQ: COLL) reported Q3 EPS of $1.34, $0.09 better than the analyst estimate of $1.25. Revenue for the quarter came in at $136.7 million versus the consensus estimate of $138.54 million.

For earnings history and earnings-related data on Collegium Pharma (COLL) click here.